Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Prescribing Criteria

GLP-1 BMI Eligibility Calculator & Target Weight

Check your clinical qualification on an interactive 4-tier medical color gauge.

Enter your height and weight in Imperial or Metric units to see your exact BMI, test whether you meet FDA labeling thresholds for Zepbound and Wegovy, and calculate your target healthy weight range.

Interactive Tool

BMI & GLP-1 Indication Screener

Check whether your Body Mass Index (BMI) matches FDA label criteria for chronic weight management medications.

Height5 ft 8 in
Weight205 lbs
100 lbs275 lbs450 lbs
Calculated BMIAdult BMI
31.2kg/m²

Obesity (BMI ≥ 30.0)

31.2
15.018.525.030.0+40.0
UnderweightHealthy ZoneOverweightObesity
Meets FDA Label Indication Threshold

Based on official FDA prescribing information (BMI ≥30, or BMI ≥27 with comorbidity), this matches labeled indication criteria for weight management GLP-1 medications.

Healthy BMI Target (18.5–24.9):121 – 163 lbs

Current weight is ~42 lbs above the standard normal BMI threshold.

Educational Notice: Calculated instantly in your browser; no personal health information is stored or transmitted. This screening tool is based on official FDA medication labels for chronic weight management and is for educational reference only, not medical diagnosis or advice. Only a licensed healthcare provider can evaluate your medical history and determine appropriate treatment.

1. The Official FDA Dual-Threshold Indication Criteria

Anti-obesity medications are not approved as cosmetic treatments. The FDA label for both tirzepatide (Zepbound) and semaglutide (Wegovy) establishes two strict diagnostic gateways:

Threshold 1: General Obesity

BMI ≥ 30.0 kg/m²

Individuals with a body mass index of 30 or greater qualify for prescription treatment regardless of whether they have a diagnosed comorbidity. Obesity itself is recognized by the AMA and NIH as a chronic, relapsing metabolic disease.

Threshold 2: Overweight + Comorbidity

BMI ≥ 27.0 kg/m² + Comorbidity

Individuals with a BMI between 27.0 and 29.9 qualify if they have at least one weight-related medical complication, including hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes.

2. Clinical Trial Benchmarks: Realistic Weight Loss Expectations

Understanding clinical trial outcomes helps patients set achievable health goals and avoid disappointment or excessive calorie deprivation:

SURMOUNT-1 Trial (Tirzepatide)

Pivotal Phase 3 Trial Benchmarks

In Eli Lilly’s 72-week Phase 3 clinical trial of 2,539 adults, participants taking the highest maintenance dose (15 mg weekly) met key metabolic and weight-management endpoints alongside structured nutritional intervention.

STEP 1 Trial (Semaglutide)

Pivotal Phase 3 Trial Benchmarks

In Novo Nordisk’s 68-week Phase 3 clinical trial of 1,961 adults, participants taking semaglutide 2.4 mg weekly achieved significant clinical improvements in weight and metabolic risk factors alongside lifestyle guidance.

3. Clinical Limitations of BMI in Modern Medicine

While BMI remains the standard screening metric adopted by regulatory agencies and health insurers, it has notable clinical limitations:

  • Body Composition Inaccuracy: BMI does not distinguish between lean skeletal muscle mass and adipose tissue. Highly athletic individuals with dense muscle mass may register as “obese”, while sedentary older adults with high visceral fat may register in the “normal” range.
  • Waist-to-Height Ratio (WHtR): Leading endocrinologists increasingly utilize waist-to-height ratio alongside BMI. Keeping waist circumference under half of your height (WHtR < 0.5) is a strong predictor of reduced visceral cardiometabolic risk.
  • Ethnic Cutoff Variations: The World Health Organization recognizes that Asian populations accumulate metabolic risk at lower body weights. For Asian adults, overweight is often classified at BMI ≥ 23 and obesity at BMI ≥ 25.

4. Recommended Clinical Action Plan by BMI Category

BMI < 25.0 kg/m² (Normal or Underweight)

You do not meet FDA criteria for GLP-1 weight loss medications. Using GLP-1s in this range is off-label, not recommended, and poses risks of excessive lean tissue depletion and nutritional deficiencies.

BMI 25.0 – 26.9 kg/m² (Overweight Without Prescription Qualification)

Falls below the FDA label threshold for anti-obesity medications. Insurance will not cover GLP-1 therapy. Focus on high-protein nutrition, structured resistance training, and metabolic lifestyle foundations.

BMI ≥ 30.0 OR BMI ≥ 27.0 with Comorbidity (FDA Prescription Eligible)

You meet official FDA label indications for chronic weight management. Next step: review baseline lab panels and estimate your insurance out-of-pocket copay before speaking with your clinician.

BMI & Indication FAQs

Frequently Asked Questions About BMI & Eligibility

What is the exact FDA approved BMI requirement for weight loss medications?↓

FDA prescribing labels for Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) specify anti-obesity therapy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with: (1) An initial BMI of 30 kg/m² or greater (classified as obesity), OR (2) An initial BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea).

Can my insurance cover GLP-1s if my BMI is 28 but I have high cholesterol?↓

Yes, provided your employer plan includes anti-obesity coverage. A BMI of 28 meets the FDA overweight threshold (≥ 27 kg/m²), and dyslipidemia (high cholesterol or elevated triglycerides) qualifies as an official weight-related comorbidity. Your prescriber must clearly document both metrics in the Prior Authorization submission.

Why does the calculator calculate a target weight based on BMI 24.9?↓

Under World Health Organization (WHO) and CDC standards, a BMI between 18.5 and 24.9 kg/m² represents the standard "Normal / Healthy Weight" classification. Our reverse calculator determines the exact weight in pounds or kilograms corresponding to BMI 24.9 for your specific height as a clinical benchmark.

How much weight can patients realistically expect to lose on GLP-1 medications?↓

In pivotal Phase 3 double-blind clinical trials, participants on tirzepatide 15 mg (SURMOUNT-1) achieved an average body weight reduction of approximately 20.9% over 72 weeks. In the STEP 1 trial, participants on semaglutide 2.4 mg achieved an average body weight reduction of approximately 14.9% over 68 weeks. Individual response varies based on adherence, lifestyle modifications, and dosage tolerance.

Are BMI cutoffs different for Asian populations?↓

Yes. The World Health Organization and Asian-Pacific guidelines recognize that individuals of South Asian and East Asian ancestry often experience elevated risks of cardiovascular disease and type 2 diabetes at lower BMI thresholds. Many clinical societies recommend defining overweight at BMI ≥ 23 kg/m² and obesity at BMI ≥ 25 kg/m² for Asian individuals.

Next Decision Steps

Check Your Financial Options & Lab Requirements

Calculate your out-of-pocket copay or prepare your 12-point clinical lab and questions checklist.